Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
On May 3, 2017, Sucampo Pharmaceuticals, Inc. (the Company)
announced its consolidated financial results for the first
quarter ended March 31, 2017. The full text of the press release
issued in connection with the announcement is furnished as
Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02 and Exhibit 99.1 to this Form
8-K shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
and is not incorporated by reference into any of the Companys
filings under the Securities Act of 1933, as amended, or the
Exchange Act, whether made before or after the date hereof,
except as shall be expressly set forth by specific reference in
any such filing.
Item 7.01 Regulation FD Disclosure.
On May 3, 2017, the Company will host a conference call with
investors to discuss the Company’s financial and operating
results for the first quarter ended March 31, 2017. The
conference call including slides will be made available to the
public via conference call and webcast. The slides from the
presentation are being furnished as Exhibit 99.2 to this Current
Report on Form 8-K.
The information in this Item 7.01 and Exhibit 99.2 to this Form
8-K shall not be deemed filed for purposes of Section 18 of the
Exchange Act or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act or the Exchange Act, except as
expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
The following exhibits relating to Item 2.02 and Item 7.01 shall
be deemed to be furnished, and not filed:
| 99.1 | Press Release issued by the Company on May 3, 2017. | |
| 99.2 | The corporate update presentation slides dated May 3, 2017. |
About Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP)
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom. It offers AMITIZA for the treatment of constipation and RESCULA for the lowering of intraocular pressure (IOP). Its products under development include cobiprostone, RTU-1096 and RTU-009. Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Recent Trading Information
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) closed its last trading session down -0.38 at 10.07 with 707,565 shares trading hands.
